1 / 1


Interaction p. HR (95% CI). CB vs. C. 0.90 (0.67, 1.20), p=0.47. < 75yo ≥ 75yo. 0.80 (0.47, 1.36), p=0.41. 0.16. CBM vs. C. < 75yo ≥ 75yo. 1.09 (0.82, 1.45), p=0.55. Abstract. Schema. 0.78 (0.46, 1.34), p=0.36. Toxicity: <75 v > 75 years. CB/CBM vs. C.

Download Presentation


An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.


Presentation Transcript

  1. Interaction p HR (95% CI) CB vs. C 0.90 (0.67, 1.20), p=0.47 < 75yo ≥ 75yo 0.80 (0.47, 1.36), p=0.41 0.16 CBM vs. C < 75yo ≥ 75yo 1.09 (0.82, 1.45), p=0.55 Abstract Schema 0.78 (0.46, 1.34), p=0.36 Toxicity: <75 v >75 years CB/CBM vs. C 0.99 (0.77, 1.27), p=0.94 0.29 < 75yo ≥ 75yo 0.79 (0.50, 1.24), p=0.31 0.40 0.60 0.80 1.00 1.20 1.40 1.60 HR With Bev better Cap alone better Background Results patients age >75 years Baseline demographics > 75 years Conclusions Methods Geriatric subgroup of AGITG MAX trial. International randomised phase III trial of capecitabine (C), bevacizumab (B) and mitomycin C (M) in 1st line metastatic colorectal cancer (CRC). T. J. Price, D. Zannino, K. Wilson, J. Simes, G. A. Van Hazel, B. A. Robinson, A. Broad, V. Ganju, S. P. Ackland, N. C. Tebbutt. The Queen Elizabeth Hospital, Adelaide, Australia; NHMRC Clinical Trials Centre, Sydney, Australia; Sir Charles Gairdner Hospital, Perth, Australia; Christchurch Hospital, Christchurch, New Zealand; Barwon Health, Geelong, Australia; Frankston Hospital, Melbourne, Australia; Newcastle MaterMisericordiae Hospital, Newcastle, Australia; Austin Health, Melbourne, Australia. On behalf of the Australasian Gastro-Intestinal Trials Group. NHMRC Clinical Trials Centre, The University of Sydney AUSTRALASIAN GASTRO-INTESTINAL TRIALS GROUP Fig 1: Kaplan-Meier curves for PFS >75 years Co-morbidity demographics > 75 years Background: In an aging population a greater proportion of geriatric patients will be considered for systemic chemotherapy. CRC is a common cancer and will be a major health issue in geriatrics. Methods: MAX, a three arm study of C v CB v CBM, found an improvement in PFS with addition of B (+/- MMC) to C¹. This analysis assesses effect of adding B (+/- MMC) to C on PFS, OS, RR and toxicity in geriatric patients (age >75y). Results: 99 patients (21%) were >75y. Number/Median age: C 37/78.5y (75.2-86), CB 32/78.7y (75.2-84.9), CBM 30/80.2y (75.2-83.4). Baseline characteristics were well balanced. 88% commenced C dose of 2000mg/m2/day, d1-14, q21 (61% for <75y). ECOG 0-1 for 88%. Co-morbidities were: (%) Ex/smoker 13/2, diabetes 15, HT 56, IHD 15, CVA/TIA 10. These are similar to reported rates in this population. Proportion receiving all 3 chemotherapy drugs at some time (5FU/Oxaliplatin/irinotecan) was 10% >75y v 20% <75y. RR, median PFS & OS reported in Table. Interaction test for OS, RR and PFS revealed no impact of age. Gd 3-4 tox for >75y C/CB/CBM respectively was (%); vomiting 5/13/3, diarrhoea 19/22/20, stomatitis 3/0/3, HT 0/3/3, thrombosis/thrombus/embolism 5/6/13, cardiac 0/6 (3 Gd5)/3. There was 1 perforation (Gd5) in C. Grade 2/3 HFS (%) was 38/59/53. One Gd 3-4 neutropenia episode in CB, no Gd 3-4 thrombocytopenia. Overall, toxicity rate similar to <75 y. Conclusion: Significant improvement in PFS with addition of B to C was seen in this geriatric population, similar to results of ITT group and those <75yrs. Treatment was well tolerated with no signal of increased toxicity when compared to those <75yrs, including VTE/ATE. Fig 2: OS age subgroup comparisons with test for interaction Median progression free survival and overall survival in patients >75 years • Aging involves a progressive decline in functional reserve and increased frequency of co-morbidity/Chronic disease. • With age, the frequency of cancer also increases. • CRC is one of the most common cancers in the population and thus we have a combination of increased frequency of CRC in older patients at a time when their general health is declining. • Patients over 75 years historically were excluded from clinical trials. • When included patients over 70 years often make up less than 20% of the total patient group, and subsequently the number of patients over 75 years is relatively small. • There is conflicting evidence as to the tolerance and outcome of chemotherapy for patients with CRC defined as elderly. • The definition of elderly varies between reports making interpretation of results difficult (eg > 65, >70 and > 75 are frequently defined age groups). • For fluoropyrimidines, toxicity differences may relate to method of delivery adding to the difficulty of interpreting results. • For capecitabine poor renal function, which declines with age, increases the risk of toxicity • With the addition of biological agents new toxicities need to be considered, in particular for bevacizumab, where there appears to be higher rates of thromboembolic disease reported. • As the MAX trial included an older population we have undertaken an analysis of the patients who we have defined as elderly or geriatric (age >75 years) to further assess the impact of age on outcome and tolerance. Response Rate PFS– subgroup comparisons with test for interaction • The MAX trial included 21% of patients who were aged >75 years. The frequency of co -morbidities were similar to those reported in the general population of this age. The majority of clinicians did choose the lower dose of capecitabine for those aged >75 years. • Significant improvement in PFS with addition of bevacizumab (+/- mitomycin C) to capecitabine was seen in this geriatric population, with similar to results reported when compared to the ITT group and those <75 years (data not shown). There was no impact of age based on the interaction test for OS, RR or PFS. • Treatment was well tolerated with no signal of increased toxicity (including VTE/ATE) when compared to those aged <75 years. • Geriatric age alone should not preclude consideration of bevacizumab as a treatment option for advanced colorectal cancer • MAX was an international, multi-centre randomised phase II/III study of capecitabine v CB v CBM which showed that there is an improvement in PFS with addition of B (+/- MMC) to Capecitabine (Tebbutt et al. JCO 2010 Jul 1;28(19):3191-8). • Eligibility included: histologically confirmed, metastatic colorectal cancer carcinoma (CRC), measurable disease, PS 0-2, adequate organ function, no prior treatment for advanced disease excepting prior adjuvant chemotherapy > 6 months prior to randomisation and informed consent. Toxicity was evaluated using National Cancer Institute Common Toxicity Criteria version 3.0 (NCIC CTCAE v3). Tumour response was evaluated using RECIST (Therasse et al. J Natl Cancer Inst 2000; 92: 205-16). Quality of life (QoL) was assessed using EORTC QLQ C30 and gastric/oesophageal modules. • Patients of >75 years of age were analysed separately in this unplanned subgroup analysis, with comparison to those aged less than 75 undertaken. This analysis primarily assesses the effect of adding B (+/- MMC) to C on PFS, OS, RR and toxicity in a geriatric set of patients (age >75y). Test for interaction of age group was performed. The MAX study is an investigator initiated study, sponsored by the AGITG. An unrestricted educational grant was provided by Roche Products Australia.

More Related